SCHEMBL4401256

SCHEMBL4401256

CCCC[S+]([O-])CCCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.56
GPR84 Q9NQS5 7/20 0.54
PPARG P37231 7/20 0.54
PPARD Q03181 7/20 0.54
PPARA Q07869 7/20 0.54
HDAC11 Q96DB2 5/20 0.54
TSHR P16473 4/20 0.54
PTPN1 P18031 3/20 0.54
FABP4 P15090 3/20 0.54
ALDH1A1 P00352 2/20 0.54
TLR2 O60603 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
KMT2A Q03164 2/20 0.54
ALOX15 P16050 2/20 0.54
HSD17B10 Q99714 2/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SLC22A8 Q8TCC7 1/20 0.54
MEN1 O00255 1/20 0.54
ESR1 P03372 1/20 0.54
PDE4A P27815 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9323099 0.91 AKR1B1 (0.50) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL9883913 0.84 AKR1B1 (0.46) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL6292864 0.83 GPR84 (0.56) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL8075910 0.83 GPR84 (0.56) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL11894646 0.81 LMNA (0.58) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL9322126 0.80 AKR1B1 (0.41) AKR1B1GPR84PPARGPPARDPPARA
SCHEMBL2581538 0.79 TSHR (0.60) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL16579413 0.78 AKR1B1 (0.50) AKR1B1GPR84PPARGPPARDPPARA
Valeric Acid SCHEMBL27658367 0.78
SCHEMBL148638 0.78 TSHR (0.40) TSHRALDH1A1TDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090305239-A1 Methods and compositions for determing a level of biologically active serum paraoxonase YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2009-12-10 US disclosed
CN-101287842-A Methods and compositions for determining bioactive serum paraoxonase levels YEDA RES & DEV (IL) 2008-10-15 CN disclosed
EP-1915457-A2 METHODS AND COMPOSITIONS FOR DETERMINING A LEVEL OF BIOLOGICALLY ACTIVE SERUM PARAOXONASE YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) 2008-04-30 EP disclosed
WO-2007020632-A2 METHODS AND COMPOSITIONS FOR DETERMINING A LEVEL OF BIOLOGICALLY ACTIVE SERUM PARAOXONASE YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305239-A1 Methods and compositions for determing a level of biologically active serum paraoxonase PON1, LPO, PNLIP AKR1B1 384/4885GPR84 4469/4885PPARG 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.